Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2017; 63(4): 80-86

EFFECASY OF BISPHOSPHONIC ACIDS IN FEMALE RATS WITH EXPERIMENTAL OSTEOPOROSIS

V.V. Povoroznyuk1, V. I. Pekhnyo2, N.V. Grygorieva1, O.M. Kozachkova2, N.V. Tsaryk2

  1. State Institution «Institute of Gerontology named after D. F. Chebotarev of NAMS Ukraine», Ukrainian ScientificMedical Center of Osteoporosis, Kyiv, Ukraine
  2. Vernadsky Institute of general and inorganic chemistry of the Ukrainian National Academy of Sciences, Kiev, Ukraine
DOI: https://doi.org/10.15407/fz63.04.080


Abstract

We evaluated the efficiency of different types of bisphosphonic acids, еthylidenebisphosphonic (EBP), aminoethylidenebisphosphonic (AEBP), 1-phenyl-1-hydroxymethylenebisphosphonic (PhHMBP) and 1-phenyl-1-fluoromethylenebisphosphonic (PhFMBP) acids compared to zoledronic acid in combination of calcium and vitamin D supplementation in female rats with experimental osteoporosis. Our results established the absence of significant changes in bone mineral density indexes in female rats after bilateral ovariectomy, which received EBF, AEBF and FenHMBF in combination with calcium and vitamin D supplements. We also showed the significant dynamics of bone mineral density indices of total body (from 0,100±0,007 tо 0,105±0,008 g/sm2 after 3 months) in the rats which receive FenFMBF with calcium and vitamin D administration. Our study requires further researches of the effectiveness of FenFMBF in the prevention and treatment of systemic osteoporosis.

Keywords: ethylidenebisphosphonic acid; aminoethylidenebisphosphonic acid; 1-phenyl-1-hydroxymethylenebisphosphonic acid; 1-phenyl-1-fluoromethylene-bisphosphonic acid; zoledronic acid; female rats; bone mineral density; experimental osteoporosis.

Full text: (PDF, in Ukrainian)

References

  1. Chan CK, Mason A, Cooper C, Dennison E. Novel advances in the treatment of osteoporosis. Br Med Bull. 2016;119(1):129-42. CrossRef PubMed PubMedCentral
    2.  
  2. Zhou J, Ma X, Wang T, Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016 Jun 7. [Epub ahead of print] CrossRef PubMedCentral
    3.  
  3. Peng J, Liu Y, Chen L, Peng K, Xu Z, Zhang D, Xiang Z. Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis. Pak J Med Sci. 2016;32(2):499-504. PubMed PubMedCentral
    4.  
  4. Serrano AJ, Bego-a L, Anitua E, Cobos R, Orive G. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013;29(12):1005-14. CrossRef PubMed
    5.  
  5. Povoroznyuk VV, Grygorieva NV, Orlyk TV et al. Osteoporosis in the practice of internist doctor. Express; 2014. [Russian].
    6.  
  6. De Colli M, Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, Cataldi A, Zara S. In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral Investig. 2016;20(8):2013-2021. CrossRef PubMed
    7.  
  7. Bortolini O, Fantin G, Fogagnolo M, Rossetti S, Maiuolo L, Di Pompo G, Avnet S, Granchi D. Synthesis, characterization and biological activity of hydroxylbisphosphonic analogs of bile acids. Eur J Med Chem. 2012;52:221-9. CrossRef PubMed
  8. Rubino MT, Agamennone M, Campestre C, Campiglia P, Cremasco V, Faccio R, Laghezza A, Loiodice F, Maggi D, Panza E, Rossello A, Tortorella P. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem. 20114;6(7):1258-68.
    9.  
  9. Povoroznyuk VV, Deduh NV, Grygorieva NV, Gopkalova IV. Experimental osteoporosis. Kyiv: Express; 2012. [Russian].
    10.  
  10. European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986.- Strasbourg, 1986. Moore SN, Tanner SB, Schoenecker JG. Bisphosphonates: from softening water to treating PXE. Cell Cycle. 2015;14(9):1354-5. PubMed PubMedCentral
    11.  
  11. Moore SN, Tanner SB, Schoenecker JG. Bisphosphonates: from softening water to treating PXE. Cell Cycle.2015;14(9):1354-5. CrossRef PubMed PubMedCentral
  12. Russell RG Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. CrossRef PubMed
    13.  
  13. Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49(1):20-33. CrossRef PubMed
    14.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.